子宫内膜癌血清肿瘤标志物研究进展  

Progress on serum tumor biomarkers of endometrial carcinoma

作　　者：陈瑞芳[1] 鹿欣[1] 

机构地区：[1]复旦大学附属妇产科医院妇瘤科,上海200111

出　　处：《国际肿瘤学杂志》2014年第5期364-367,共4页Journal of International Oncology

摘　　要：血清肿瘤标志物对子宫内膜癌的早期诊断、治疗、术前评估及患者预后预测及肿瘤复发监测等均有重要意义.血清糖类抗原125、人附睾分泌蛋白4是目前较公认的与子宫内膜癌的分期、转移及预后等密切相关的肿瘤标志物.此外,血清微小RNA具有稳定性好、组织特异性高的特点,组学技术能从整体角度分析肿瘤的发生发展,随着这两方面研究的逐步深入,有望找到新的敏感性和特异性均较高的子宫内膜癌血清肿瘤标志物.Serum tumor biomarkers are significant for the early diagnosis and treatment,preoperative evaluation,prognosis prediction and relapse surveillance of endometrial carcinoma.Recently,serum CA125 and human epididymal secretory protein 4 are widely recognized as closely related with staging,metastasis and prognosis of endometrial cancer.In addition,the serum miRNAs are characterized by their features of high stability and specificity.Omics studies will be helpful for the general assessment of the initiation and progression of endometrial cancer.Insights into these two aspects will facilitate the identifications of new biomarkers with higher sensitivity and specificity for endometrial carcinoma.

关 键 词：子宫内膜肿瘤 肿瘤标记 生物学 血清 

分 类 号：R737.33[医药卫生—肿瘤]